Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin

PaperCitations, authors & open-access status

Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 261 citations, 2016 year and green oa status.